HealthPhoto: HT WorldFridge-Free Vaccines Could Expand Access but Face Challenges in Africa
In April 2025, UK biotech company Stablepharma began human trials of a tetanus-diphtheria vaccine stable without refrigeration. This innovation could improve vaccine access in African regions with limited electricity and cold storage infrastructure. Experts highlight that maintaining the cold chain, keeping vaccines between 2°C and 8°C during transport and storage, is critical but challenging in such settings, risking vaccine potency and safety.
HT World··Stellenbosch


